Topical analgesia for acute otitis media by Foxlee, R et al.
Bond University
Research Repository
Topical analgesia for acute otitis media
Foxlee, R; Johansson, A; Wejfalk, J; Dooley, L; Del Mar, C
Published in:
Cochrane Database of Systematic Reviews
DOI:
10.1002/14651858.CD005657.pub2
Published: 19/07/2006
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Foxlee, R., Johansson, A., Wejfalk, J., Dooley, L., & Del Mar, C. (2006). Topical analgesia for acute otitis media.
Cochrane Database of Systematic Reviews, (3), 1-42. [CD005657].
https://doi.org/10.1002/14651858.CD005657.pub2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
Bond University
ePublications@bond
Faculty of Health Sciences & Medicine Publications Faculty of Health Sciences & Medicine
7-19-2006
Topical analgesia for acute otitis media
Ruth Foxlee
University of York
Ann-Charlotte Johansson
ABIGO Medical AB, Askim, Sweden
Jessika Wejfalk
Octean AB, Göteborg , Sweden
Liz Dooley
Bond University, Liz_Dooley@bond.edu.au
Chris Del Mar
Bond University, chris_del_mar@bond.edu.au
Follow this and additional works at: http://epublications.bond.edu.au/hsm_pubs
Part of the Otorhinolaryngologic Diseases Commons
This Journal Article is brought to you by the Faculty of Health Sciences & Medicine at ePublications@bond. It has been accepted for inclusion in
Faculty of Health Sciences & Medicine Publications by an authorized administrator of ePublications@bond. For more information, please contact
Bond University's Repository Coordinator.
Recommended Citation
Ruth Foxlee, Ann-Charlotte Johansson, Jessika Wejfalk, Liz Dooley, and Chris Del Mar. (2006)
"Topical analgesia for acute otitis media" ,, .
http://epublications.bond.edu.au/hsm_pubs/51
Topical analgesia for acute otitis media (Review)
Foxlee R, Johansson A, Wejfalk J, Dawkins J, Dooley L, Del Mar C
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2007, Issue 2
http://www.thecochranelibrary.com
1Topical analgesia for acute otitis media (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
T A B L E O F C O N T E N T S
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2CRITERIA FOR CONSIDERING STUDIES FOR THIS REVIEW . . . . . . . . . . . . . . . . . .
3SEARCH METHODS FOR IDENTIFICATION OF STUDIES . . . . . . . . . . . . . . . . . . .
4METHODS OF THE REVIEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5DESCRIPTION OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODOLOGICAL QUALITY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8POTENTIAL CONFLICT OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10Characteristics of included studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12Characteristics of excluded studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13Comparison 01. Anaesthetic versus placebo . . . . . . . . . . . . . . . . . . . . . . . . . .
13Comparison 02. Anaeshethic versus naturopathic . . . . . . . . . . . . . . . . . . . . . . . .
13INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13COVER SHEET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15GRAPHS AND OTHER TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15Figure 01. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
16Analysis 01.01. Comparison 01 Anaesthetic versus placebo, Outcome 01 25% reduction in ear pain . . . . . .
16Analysis 01.07. Comparison 01 Anaesthetic versus placebo, Outcome 07 50% reduction in ear pain . . . . . .
17Analysis 02.01. Comparison 02 Anaeshethic versus naturopathic, Outcome 01 Mean pain score, day 1 . . . . .
18Analysis 02.02. Comparison 02 Anaeshethic versus naturopathic, Outcome 02 Mean pain score, day 2 . . . . .
19Analysis 02.03. Comparison 02 Anaeshethic versus naturopathic, Outcome 03 Mean pain score, day 3 . . . . .
iTopical analgesia for acute otitis media (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
Topical analgesia for acute otitis media (Review)
Foxlee R, Johansson A, Wejfalk J, Dawkins J, Dooley L, Del Mar C
This record should be cited as:
Foxlee R, Johansson A, Wejfalk J, Dawkins J, Dooley L, Del Mar C. Topical analgesia for acute otitis media. Cochrane Database of
Systematic Reviews 2006, Issue 3. Art. No.: CD005657. DOI: 10.1002/14651858.CD005657.pub2.
This version first published online: 19 July 2006 in Issue 3, 2006.
Date of most recent substantive amendment: 19 May 2006
A B S T R A C T
Background
Acute otitis media (AOM) is a spontaneously remitting disease for which pain is the most distressing symptom. Antibiotics are now
known to have less benefit than previously assumed.
Objectives
To assess the effectiveness of topical analgesia for AOM.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 2, 2006), MEDLINE (1966
to May Week 3 2006), EMBASE (1990 to December 2005) and LILACS (1982 to September 2005) without language restriction, and
the reference lists of articles. We also contacted manufacturers and authors.
Selection criteria
Double-blind randomised or quasi-randomised controlled trials comparing an otic preparation with an analgesic effect (excluding
antibiotics) versus placebo or an otic preparation with an analgesic effect (excluding antibiotics) versus any other otic preparation with
an analgesic effect, in adults or children presenting at primary care settings with AOM without perforation.
Data collection and analysis
Potential studies were screened independently and trial quality was assessed by three authors, and differences were resolved by discussion.
Data was then independently extracted from the trials selected by two authors. We contacted the authors of three trials to acquire
additional information not available in published articles.
Main results
Our searches yielded 356 records; four trials met our criteria. One trial with 54 participants compared treatment with anaesthetic ear
drops versus an olive oil placebo immediately at diagnosis. All patients were also given paracetamol. There was a statistically significant
pain reduction of 25% in those receiving anaesthetic drops 30 minutes after instillation. Three trials (with one common co-author)
compared anaesthetic ear drops with naturopathic herbal ear drops in 274 patients. One of these trials also used antibiotics in both
groups. There were statistically significant differences at instillation of drops, or 15 or 30 minutes after the instillation (or both) on one
to three days after diagnosis, always favouring the naturopathic group in each trial.
Authors’ conclusions
The evidence from these four randomised controlled trials, only one of which addresses the most relevant question of primary effec-
tiveness, is insufficient to know whether ear drops are effective or not.
P L A I N L A N G U A G E S U M M A R Y
Treating the pain of acute middle ear infection is difficult
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Antibiotics and oral pain killers make little difference. Some advocate ear drops with local anaesthetic. Only four trials were found with
adequate methods, and only one compared anaesthetic drops to placebo. The other three compared anaesthetic drops to naturopathic
drops. There was not enough information to be sure whether the drops are effective or not effective. More good quality trials are needed.
B A C K G R O U N D
Acute otitis media (AOM) is a very common disease of childhood
and a leading cause of visits to the family doctor and antibiotic
prescribing for children in high-income countries (Charles 2004;
Froom 1997; Glasziou 2003; Pirozzo 2004). Although it is difficult
to establish a global estimate, childhood incidence ranges between
17% and 32% per year (Pirozzo 2004).
AOM is characterised by inflammation and effusion of the middle
ear accompanied by varying degrees of local pain, fever, irritabil-
ity and possible erythema and deafness. The onset of symptoms
and signs is rapid and the acute infection usually resolves within
days. The illness can affect people at any age but occurs mainly in
children, where incidence peaks between 6 and 15 months (Klein
1989). Although the morbidity rate is high, the mortality rate
for healthy children in high-income countries is low. Suppurative
complication rates are also low (Marcy 2001) and severe illness
requiring antibiotic therapy only occurs in about 2.7% of chil-
dren (Van Buchem 1985). This may not be true of low-income
countries where the burden of AOM is heavier because access to
medical care is limited and the risk of complications is higher
(Berman 1995; Klein 2001). The impact of AOM is also greater
among some indigenous populations living in high-income coun-
tries (WHO/CIBA 1996). Potential hearing loss is of particular
concern in countries where illiteracy is high and the comprehen-
sion of normal speech is vital (Klein 2001).
Antibiotics have been a mainstay of treatment based on a patho-
physiological model (Pirozzo 2004). A Cochrane review chal-
lenged this approach to treatment by demonstrating that the ben-
efit from antibiotics are modest and may not outweigh their risks
(Glasziou 2003). Approximately 17 children needed to be treated
to prevent one child experiencing pain after two to seven days
(Glasziou 2003). Another systematic review showed that 60% of
children will improve spontaneously in 24 hours without any an-
tibiotic treatment and 80% of cases will resolve within three days
(Rosenfeld 2003). Antibiotics also threaten adverse effects to the
individual, such as diarrhoea, stomach pain, rash and vomiting.
Antibiotic use also inevitably promotes resistance by natural selec-
tion, thus limiting their usefulness for future generations (Nasrin
2002).
In recent years there has been a trend away from the prescription of
antibiotics for all AOM sufferers. Generally, children over the age
of two years can be treated with analgesia (Glasziou 2003). In an
effort to minimise adverse effects and help guard against the selec-
tion of resistant strains some current guidelines advise against rou-
tine antibiotic treatment for uncomplicated AOM (DoH 2000;
SIGN 2003; Spicer 2003). The AAP guidelines (AAP 2004) offer
the option, not recommendation, of initially observing selected
children, primarily those aged two years or older with non-severe
illness.
Even though AOM is not a life-threatening illness, the symptoms
may be very distressing for sufferers, usually children, and their
parents/carers. Pain is a common aspect of otitis media because the
ear is so well-innervated with pain-sensitive structures. In AOM
increased pressure in the middle ear stretches these structures, thus
leading to the idea that topical analgesia can provide pain relief
(Schecter 2003). The element of AOM-associated pain can some-
times be a peripheral concern for physicians but it is central to the
patient’s experience of the illness (Schecter 2003) and a common
reason to seek treatment. Topical treatments may be prescribed
or bought over-the-counter. In the context of reduced antibiotic
prescribing for uncomplicated AOM it is worthwhile assessing the
effectiveness of these topical treatments as an alternative to the
routine prescription of antibiotics, particularly when symptomatic
pain relief is such an important treatment outcome for patients
and parents/carers.
O B J E C T I V E S
The aim of this review was to:
(i) assess the effectiveness of topical analgesia in adults and children
suffering from acute otitis media without perforation;
(ii) assess whether different topical analgesic preparations differ in
effect.
The primary outcome measures were severity and duration of pain.
Secondary measures were parental satisfaction, days missed from
school or work (for both children and parents/carers) and adverse
events.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
All double-blind randomised or quasi-randomised controlled tri-
als.
Types of participants
Adults and children presenting at primary care settings, suffering
from acute otitis media without perforation.
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Types of intervention
(i) Any otic preparation with an analgesic effect (excluding antibi-
otics) versus placebo.
(ii) Any otic preparation with an analgesic effect (excluding antibi-
otics) versus any other otic preparation with an analgesic effect.
Types of outcome measures
Data extraction focused on patient-relevant outcomes. The pri-
mary outcome measures were severity and duration of pain. Sec-
ondary measures included at least one of the following: parental
satisfaction, days missed from school or work and adverse events.
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Acute Respiratory Infections Group methods used
in reviews.
We searched the Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library Issue 2, 2006), MEDLINE
(1966 to May Week 3 2006), EMBASE (1990 to December
2005) and LILACS (1982 to September 2005) without language
restrictions and the reference lists of articles. We also contacted
manufacturers and authors.
MEDLINE (Ovid)
1 exp Otitis Media/
2 (otitis media or AOM or OM).mp.
3 or/1-2
4 exp Benzocaine/
5 benzocaine.mp.
6 exp Tetracaine/
7 amethocaine.mp.
8 exp Lidocaine/
9 lidocaine.mp.
10 (anesthetic or anaesthetic).mp.
11 topical analgesi$.mp.
12 exp Antipyrine/
13 (antipyrine or phenazone).mp.
14 (americaine otic or aurafair or auralgan or auralgesic or
auraphene or aurisan or auroto or dolotic or lanaurine otocain or
omedia or oticaine or otigesic or otocalm or Rx-Otic or sedaural
or tympagesic).mp.
15 or/4-14
16 exp Anti-Inflammatory Agents/
17 (antiinflammator$ or anti inflammator$).mp.
18 or/16-17
19 exp Administration, Topical/
20 (topical or otic).mp.
21 or/19-20
22 18 and 21
23 exp Histamine H1 Antagonists/
24 (antihistamine$ or anti-histamine$).mp.
25 or/23-24
26 25 and 21
27 exp Steroids/
28 steroid$.mp.
29 or/27-28
30 29 and 21
31 15 or 22 or 26 or 30
32 3 and 31
EMBASE (WebSPIRS)
#1 ’otitis-media’ / all subheadings in DEM,DER,DRM,DRR
#2 (otitis media or AOM or OM) in ti
#3 (otitis media or AOM or OM) in ab
#4 #1 or #2 or #3
#5 ’benzocaine-’ / all subheadings in DEM,DER,DRM,DRR
#6 (benzocaine in ti) or (benzocaine in ab)
#7 ’tetracaine-’ / all subheadings in DEM,DER,DRM,DRR
#8 (amethocaine in ti) or (amethocaine in ab)
#9 ’lidocaine-’ / all subheadings in DEM,DER,DRM,DRR
#10 (lidocaine in ti) or (lidocaine in ab)
#11 (anesthetic or anaesthetic) in ti
#12 (anesthetic or anaesthetic) in ab
#13 (topical analgesi*) in ti
#14 (topical analgesi*) in ab
#15 ’phenazone-’ / all subheadings in DEM,DER,DRM,DR)
#16 (antipyrine in ti) or (antipyrine in ab)
#17 ’auralgan-’ / all subheadings in DEM,DER,DRM,DR)
#18 (americaine otic or aurafair or auralgan or auralgesic or
auraphene or aurisan or auroto or dolotic or lanaurine otocain or
omedia or oticaine or otigesic or otocalm or Rx-Otic or sedaural
or tympagesic) in ti
#19 (americaine otic or aurafair or auralgan or auralgesic or
auraphene or aurisan or auroto or dolotic or lanaurine otocain or
omedia or oticaine or otigesic or otocalm or Rx-Otic or sedaural
or tympagesic) in ab
#20 #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or
#14 or #15 or #16 or #17 or #18 or #19
#21 ’antiinflammatory-agent’ / all subheadings in
DEM,DER,DRM,DRR
#22 (antiinflammator* or anti inflammator*) in ti
#23 (antiinflammator* or anti inflammator*) in ab
#24 #21 or #22 or #23
#25 ’topical-drug-administration’ / all subheadings in
DEM,DER,DRM,DRR
#26 (topical or otic) in ti
#27 (topical or otic) in ab
#28 #25 or #26 or #27
#29 #24 and #28
#30 ’antihistaminic-agent’ / all subheadings in
DEM,DER,DRM,DRR
#31 (antihistamine* or anti-histamine*) in ti
#32 (antihistamine* or anti-histamine*) in ab
#33 #30 or #31 or #32
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#34 #28 and #33
#35 ’steroid-’ / all subheadings in DEM,DER,DRM,DRR
#36 (steroid in ti) or (steroid in ab)
#37 #35 or #36
#38 #28 and #37
#39 #20 or #29 or #34 or #38
#40 #4 and #39
The references of all included trials were scanned to identify other
potentially relevant studies. We contacted the manufacturers of
topical analgesic preparations and authors of published trials to
enquire if they were aware of any unpublished trials. Only one
reply was received stating that the company had no additional
unpublished data about their product.
M E T H O D S O F T H E R E V I E W
Quality assessment
Combined searches of MEDLINE, EMBASE, CENTRAL and
LILACS retrieved 356 citations. Titles and abstracts were reviewed
independently by two authors (ACJ and JW) to exclude trials
which clearly did not meet the inclusion criteria of the review. If
either author felt that the trial might possibly meet the criteria,
the full paper was obtained for further examination. Full copies
of 29 studies were reviewed; eight trials were identified as possibly
meeting the review inclusion criteria and were appraised using a
modification of a published method (Chalmers 1990). The items
were assessed for the following four characteristics:
1. Method of treatment assignment
a. Correct, blinded,
randomisation method described OR randomised, double-blind
stated AND group similarity documented.
b. Blinding and randomisation stated, but method not described
OR suspect technique, for example, envelope.
c. Randomisation claimed but not described, and investigator not
blinded.
d. Randomisation not mentioned.
2. Control of selection bias after treatment assignment
a. Intention-to-treat analysis AND full follow up.
b. Intention-to-treat analysis AND less than 15% loss to follow
up.
c. Analysis by treatment received only OR no mention of
withdrawals.
d. Analysis by treatment received AND no mention of
withdrawals OR more than 15% withdrawals/loss-to-follow
up/post-randomisation exclusions.
3. Blinding
a. Blinding of (i) outcome assessor AND (ii) patient AND (iii)
care giver.
b. Blinding of (i) outcome assessor OR (patient AND care giver).
c. Blinding impossible, or unclear if blinding was carried out.
d. Blinding not done.
4. Outcome assessment
a. All patients had standardised assessment.
b. No standardised assessment OR not mentioned.
The studies were assessed independently by three authors (JD, ACJ
and JW) and differences of opinion were resolved by discussion.
Only four trials fulfilled the criteria (Hoberman 1997; Sarrell
2001; Sarrell 2003a; Sarrell 2003b), two trials were reported in one
paper (Sarrell 2003a; Sarrell 2003b). An unpublished trial (Matz
2001a) was identified through personal communications but was
excluded. Reasons for exclusion for all papers, whether appraised
or not, are detailed in the ’Characteristics of excluded studies’
table. The references of the included trials were scanned to identify
other potentially relevant studies. Letters of enquiry were sent to
17 companies that were listed in MicroMedex as manufacturers of
otic pain relief preparations, in order to locate unpublished trials
or data. Only one reply was received stating that the company had
no additional unpublished data about their product.
Data extraction
All data from the studies were independently extracted by two
authors (ACJ and JW), using data extraction forms designed
and validated by the authors. Differences were resolved by
discussion. Attempts to obtain missing data from trial authors were
unsuccessful.
Data analysis
Pain was measured as a dichotomous outcome in one trial and as
a continuous outcome in the other three trials. Forest plots for the
trial with dichotomous outcomes were drawn using relative risk
and 95% confidence interval (CI). Trials measuring continuous
outcomes were combined and analysed using weighted mean
differences (WMD) and 95% CI. Heterogeneity between trials
using continuous data was tested using both fixed and random
effects models in Review Manager software and a random effects
model was used in the final analyses as heterogeneity was identified.
Our attempts to obtain individual patient data in order to
reconstruct an intention-to-treat analysis in three of the trials were
unsuccessful.
Subgroup analyses
The planned subgroup analyses of the primary outcomes were:
1) Age groups; a) children aged less than 24 months at time of
randomisation; b) children aged 24 months up to 18 years at time
of randomisation; c) adults aged 18 years and over at time of
randomisation.
2) Different types of otic preparations with an analgesic
effect - local anaesthetics, antihistamines, nonsteroidal anti-
inflammatories, steroids or complementary medicines.
3) Concurrent use of antibiotics.
We were unable to carry out any subgroup analyses because there
were too few trials and insufficient data in the categories outlined
in the protocol.
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D E S C R I P T I O N O F S T U D I E S
Of the eight papers appraised, four did not meet the inclusion
criteria of the review.
Two trials (Laxdal 1970; Matz 2001a) were excluded because they
compared a topical otic preparation to oral antibiotics. One trial
(Matz 2001a) assessed pain and parental satisfaction in children
with AOM treated with either anaesthetic ear drops or amoxicillin
and the trial was not double-blinded. Another trial (Laxdal 1970),
which compared anaesthetic ear drops to penicillin, did not assess
pain and was not double-blinded. A third trial (Weippl 1985)
compared the analgesic effect of suprofen syrup to anaesthetic
ear drops. This trial was neither randomised nor double-blinded
and as the syrup was administered orally it was excluded. The
fourth trial (Abramson 1969) examined topical anaesthesia for the
tympanic membrane prior to surgery.
Four trials fulfilled the review inclusion criteria; of these, two were
found in the same paper (Sarrell 2003a; Sarrell 2003b). One of the
trials (Hoberman 1997) evaluated the efficacy of anaesthetic ear
drops (antipyrine, benzocaine and glycerine) for treating ear pain
in children with acute otitis media. Fifty-four children aged 5 to
19 years, with ear pain and a clinical diagnosis of AOM, who pre-
sented to the primary care settings or the emergency department
of the Children’s Hospital of Pittsburgh in Pennsylvania, were en-
rolled in the study. Children were excluded if they had received
any analgesic medication or ear drops within the preceding five
hours; were allergic to acetaminophen, antipyrine, or benzocaine;
had otorrhoea, an eardrum perforation, or ventilation tubes; had
ear disease other than AOM; or were judged unable to use a visual
analog pain scale reliably.
Eligible children in this trial (Hoberman 1997) were randomly
assigned to either five drops of the anaesthetic preparation or olive
oil placebo. All children were also treated with 15 mg/kg of ac-
etaminophen as a single dose. Ear pain was assessed upon entry to
the study, then 10, 20 and 30 minutes after instillation and an av-
erage ear pain score was determined. Two visual analog scales were
used; a 10 cm horizontal line and a 10 cm colour scale ranging
from white (indicating no pain) through gradations of red to dark
red (indicating severe pain). A 1 cm span in each scale was equiva-
lent to an ear pain point. A pain score of at least three out of ten at
the onset of treatment was required for study participation. Four
measures were used: 1) proportion of subjects achieving 50% pain
reduction; 2) proportion of subjects achieving 25% pain reduc-
tion; 3) proportion of participants showing a one or more point
reduction; 4) mean score over time. No drop outs were reported
but data was missing for a child at one time point.
Three trials investigated the efficacy of naturopathic herbal extracts
in the management of ear pain associated with AOM. One of these
(Sarrell 2001) included 110 children aged between 6 to 18 years
with ear pain and for whom a clinical diagnosis of otitis media
was made, enhanced by tympanometry. Children were excluded
if they had used any ear drops or analgesics within the preceding
four hours; had a known allergy to either of the preparations being
tested; had otorrhoea, eardrum perforation, ventilation tube(s),
known immune deficiency, a past history of complicated AOM, a
history of treated or untreated ear disease in the two weeks prior
to enrolment in the study or were unable to reliably use a visual
analog pain scale.
Participants in this trial (Sarrell 2001) were randomised to receive
either anaesthetic ear drops (amethocaine, phenazone and glyc-
erine) or naturopathic herbal extract ear drops (Allium sativum,
Verbascum thapsus, Calendula flores and Hypericum perforatum in
olive oil). Five drops of either solution were instilled into the ear
three times daily for three days. All children were treated with
acetaminophen (15 mg/kg given as a single dose). Ear pain re-
duction was assessed using two visual analog scales, graded 1 to
10, with 1 signifying no pain and 10 signifying excruciating pain.
Measurements of both scales were recorded separately at each time
point, and then averaged to determine an overall ear pain score
for each treatment group. Pain was measured upon diagnosis of
AOM and then daily for three days; before instillation and then
15 and 30 minutes after the first instillation each day. A pain score
of at least three at the onset of treatment was required for study
participation. The participants were educated in the use of the
pain scale and telephone interviews were conducted with parents
24 and 48 hours after the treatment period. Seven children were
not included in the final analysis (five due to non-compliance and
two because they were overcome by the smell of the ear drops).
In the second trial by Sarrell (Sarrell 2003a), 90 children aged 5 to
18 years with ear pain were enrolled. The diagnosis was primarily
clinical, enhanced by tympanometry. In addition to the exclusion
criteria in the first trial (Sarrell 2001), children with otologic or
craniofacial malformations were also excluded. The children were
assigned by computer-numbered randomisation to receive either
anaesthetic ear drops (amethocaine, phenazone and glycerine) or
naturopathic herbal extract ear drops (Allium sativum, Verbascum
thapsus, Calendula flores, Hypericum perfoliatum, Lavandulla offic-
inalis, and vitamin E in olive oil). The dosing schedule was five
drops three times daily for three days. Ear pain was assessed by us-
ing a linear numbered scale, from 1 (no pain) to 10 (worst possible
pain), a scale of five facial expressions, and a colour scale. Outcome
measurement was conducted as per the 2001 trial. Four children
were excluded from the final analysis because of non-compliance
(they forgot to take the medicine, or could not be reached for the
follow up interview).
In the third trial by Sarrell (Sarrell 2003b), 90 children aged 5 to
18 years with ear pain were enrolled. The diagnosis and exclusion
criteria were as outlined above. Computer-numbered randomi-
sation was used to assign children to treatment. Anaesthetic ear
drops (five drops three times daily for three days ) plus oral amox-
icillin (80 mg/kg/day divided into three doses) were compared
with naturopathic herbal extract ear drops (five drops three times
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daily for three days) plus oral amoxicillin (80 mg/kg/day divided
into three doses). Ear pain assessment and outcome measures were
conducted as per Sarrell 2003a. Five children were excluded from
the final analysis because of non-compliance (they forgot to take
the medicine, or could not be reached for the follow up interview).
M E T H O D O L O G I C A L Q U A L I T Y
The comparison of anaesthetic ear drops to placebo (Hoberman
1997), was double-blind but method of randomisation and allo-
cation concealment were not mentioned. The authors calculated
that 27 subjects per study arm were required to detect a clini-
cally significant reduction after 10, 20 and 30 minutes of at least
50% from the baseline score. No patients were reported to have
dropped out, but data were missing for one of the children at the
20 minutes evaluation time point. This child, representing 3.7%,
was not accounted for in the final analysis of that time point. The
anaesthetic and placebo groups were comparable in age, sex, race,
laterality of AOM and baseline ear pain score.
Method of randomisation was only mentioned in two of the tri-
als (Sarrell 2003a; Sarrell 2003b) which reported the use of com-
puter-generated randomisation. Allocation concealment was not
discussed in either of the trials by Sarrell (Sarrell 2001, Sarrell
2003a, Sarrell 2003b). All trials were double-blinded but no de-
tails were provided for the first trial (Sarrell 2001). In the later
trials (Sarrell 2003a, Sarrell 2003b) all ear drops were placed in
identical bottles, the contents of which were unknown to both the
participants and the study nurse. It is unclear whether this was
also true of the physician who evaluated and treated the patients
and recorded all of the data. Neither of the trials reported a power
calculation.
None of the naturopathic herbal extract trials (Sarrell 2001, Sarrell
2003a, Sarrell 2003b) carried out an intention-to-treat analysis.
Seven children (6.4%) were excluded after randomisation in Sarrell
2001 but no information about which groups they came from
was provided. We contacted the authors on this matter but no
further information was forthcoming. Four out of 90 children
enrolled in Sarrell 2003a were excluded due to non-compliance
(one (2.2%) in the naturopathic group and three (6.7%) in the
anaesthetic group). Five out of 90 children enrolled in the Sarrell
2003b trial were excluded due to non-compliance (three (6.7%) in
the naturopathic ear drops plus antibiotics group and two (4.4%)
in the anaesthetic ear drops plus antibiotics group). The groups
were similar in terms of baseline characteristics (age, sex, laterality
of AOM and initial ear pain score) in all three trials.
R E S U L T S
The primary outcome measures (severity and duration of pain)
specified in our protocol matched those in the included trials. But
none of our selected secondary outcomes (parental satisfaction,
and days missed from school or work) were addressed in these
trials. Nor were any possible adverse events reported, (including
stinging, pain, dermatitis and sensitisation (Rosenfeld 2005)).
In the trial that compared anaesthetic ear drops with placebo
(Hoberman 1997), the anaesthetic ear drops were favoured at each
time point, irrespectively of which outcome measure was used ((1)
50% pain reduction; (2) 25% pain reduction; (3) one or more
point reduction; (4) mean score over time)). However, the only
between-group difference that reached statistical significance was
the proportion of subjects with a 25% reduction in pain after 30
minutes (P value = 0.02). The reduction in mean ear pain score
showed good agreement according to the two pain measurement
scales. Within-group differences across time were all statistically
significant (P value less than 0.05).
In comparing anaesthetic ear drops to naturopathic drops (Sarrell
2001; Sarrell 2003a; Sarrell 2003b), a reduction in pain was seen
over time in both treatment groups across all trials. In the first trial
(Sarrell 2001), the anaesthetic group showed a mean pain score of
8.53 at baseline. It had declined to 5.6 15 minutes after instillation,
and to 4.3 30 minutes after instillation on day 1. The naturopathic
group showed a mean pain score of 8.46 at baseline, 4.8 15 minutes
after instillation, and 3.1 30 minutes after instillation.
In the second trial (Sarrell 2003a), the anaesthetic group had a
mean pain score of 7.8 at baseline, 4.3 15 minutes after instillation,
and 2.9 30 minutes after instillation day 1. The naturopathic group
had a mean pain score of 8.4 at baseline, 4.7 15 minutes after
instillation, and 3.0 30 minutes after instillation.
In the third trial (Sarrell 2003b), the group that was given anaes-
thetic drops plus oral amoxicillin showed a mean pain score of 9.1
at baseline, 6.7 15 minutes after instillation, and 5.6 30 minutes
after instillation on day 1. The group that was given naturopathic
drops plus oral amoxicillin showed a mean pain score of 8.7 at
baseline, 5.2 15 minutes after instillation, and 3.5 30 minutes after
instillation. According to the above results, it is a clear drop in pain
in all the groups the first day. The following two days also show
a drop in pain, but the reduction is not as pronounced. Initially
we believed we could not pool the data because the two arms of
Sarrell 2003b used antibiotics. However there is strong evidence
to suggest that antibiotics make no difference to the level of pain
within the first 24 hours (Glasziou 2003), therefore we performed
a meta-analysis using all the Sarell trials for day 1 only.
The first trial (Sarrell 2001) achieved statistical significance be-
tween the groups at 30 minutes on day 1 (P value less than 0.01),
favouring the naturopathic ear drops. In the second trial (Sarrell
2003a) there was a significant difference in pain on day 3 (P value
less than 0.001), 30 minutes after instilling the drops, also sup-
porting naturopathic ear drops. Antibiotics were given to both
groups in the third trial (Sarrell 2003b), in which the naturopathic
ear drops were favoured again at each time point, and the differ-
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ences reached statistical significance at 15 and 30 minutes on day
1 (P value less than 0.01); before instillation on day 2 (P value less
than 0.001); before (P value less than 0.05) and 30 minutes after
instillation on day 3 (P value less than 0.01). See Figure 01.
We performed a meta-analysis on two of the trials (Sarrell 2001;
Sarrell 2003a). Forest plots showed that there was significant het-
erogeneity.
D I S C U S S I O N
Sufficient pain relief early in the course of AOM provides poten-
tial benefits for the child as well as the parents, particularly since
the reduction in pain is such an important treatment outcome.
Systemic analgesia is used in the management of pain, but it has
a delayed effect. The late onset may allow for a pain response
pathway to become established, which might result in a prolonged
discomfort. Therefore, there is a need for a quick relief of pain.
A review found that antibiotics did not alter pain within the first
day and only slightly reduced it in the few days following and that
antibiotic treatment had no early impact and a modest overall im-
pact on the clinical course of acute otitis media (Glasziou 2003).
Because of the minor contribution of antibiotics, the promotion
of resistance and the possible adverse effects, antibiotics are not
always the best treatment option for AOM.
Although no adverse events were reported, these trials were not
particularly well designed to detect any such events. Firstly, it was
an inclusion criterion that tympanic membranes had to be intact.
We know nothing about whether the drugs could cause ototox-
icity through perforated tympanic membranes. Any late adverse
events were not recorded. Numbers were also very small to detect
anything other than very common events.
There is a surprising shortage of information about the efficacy
of analgesic ear drops for AOM. There was a rapid reduction in
pain after instilling ear drops in both intervention and control
groups in all four trials. It is hard to know if this was the result of
the natural course of the illness; the placebo effect of being in a
clinical setting; the ear drops or the soothing effect of (any) liquid
on the inflamed tympanic membrane. It is also possible that the
pain reduction resulted from the concomitant administration of
oral acetaminophen. However, the reduction seen at 15 minutes
on day one is not likely an effect of acetaminophen, for which
complete absorption rate ranges from 23 to 60 minutes (Watson
1989). Its about a 50% reduction. Despite the potential bias, it
does give an estimate of the upper limit of effectiveness. A different
trial design is needed to disentangle this, with perhaps a no-ear-
drop-control group as well as a placebo control.
Reporting in the four included trials was poor for some quality
elements. Allocation concealment was not mentioned in any of
the papers, and a lack of concealment is a potential source of bias
in all studies. Intention-to-treat was not performed in three of the
trials (Sarrell 2001; Sarrell 2003a; Sarrell 2003b) but the number
of drop-outs was given in each trial. One of the trials (Sarrell 2001)
did not specify which arm the patients dropped out of, but even
in a worst case scenario, the drop-out rate in that trial would have
been less than 15%. Although these losses are within conventional
limits it would have been reassuring to know that they did not all
occur in one arm. The drop-out rate in the other two trials did not
exceed 7% (Sarrell 2003a; Sarrell 2003b). To be able to reconstruct
an intention-to-treat analysis (Sarrell 2001; Sarrell 2003a; Sarrell
2003b), individual patient data was required. Attempts to contact
the authors for further information were unsuccessful.
The four trials (Hoberman 1997; Sarrell 2001; Sarrell 2003a; Sar-
rell 2003b) all used two visual analog scales to assess pain. Pain is
a subjective outcome and related to many variables, therefore self-
reporting is considered as the most trustworthy way to measure
pain (Mathews 1993). Children older than five years of age were
selected to participate in the trials, because younger children have
a limited ability to describe their pain experience (Mathews 1993).
However, some clinicians will be concerned about generalising the
results to the population most at risk.
Meta-analysis on two of the naturopathic drop trials (Sarrell 2001;
Sarrell 2003a) revealed significant heterogeneity. The remaining
naturopathic drop trial (Sarrell 2003b) used antibiotics in both
groups, excluding the possibility of combining their data with the
two other trials (Sarrell 2001; Sarrell 2003a).
All four trials showed only marginal differences between groups,
insufficient to reach convincing statistical significance, or even
clinical significance according to the a priori differences set by the
investigators of the placebo controlled trial (Hoberman 1997).
Finally, one must ask whether naturopathic preparations have
known analgesic properties. We contacted a practitioner of home-
opathy to ask about this (Michelle Morgan of Mediherb) who told
us (personal communication, 15 February 2006) that at least some
of the compounds have a reputation for analgesic properties when
used topically (viz Calendula flower, Mullein flower and Lavender
oil). Other explanations of the intervention effect of naturopathic
preparations other than a real effect require impugning the quality
or fairness of the trial.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence from these four randomised controlled trials, only
one of which addresses the most relevant question of primary
effectiveness, is insufficient to know whether ear drops are effective
or not. If future trials find ear drops to be even only moderately
effective, for managing the pain caused by AOM, the treatment is
likely to be safer, cheaper and more accessible than antibiotics.
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Implications for research
High quality, placebo controlled trials need to be conducted in
order to better establish the safety and efficacy of analgesic drops
for AOM.
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T A B L E S
Characteristics of included studies
Study Hoberman 1997
Methods R= randomisation claimed, but method not described.
Baseline comparability documented. Investigators were unaware of treatment assignment.
Intention to treat analysis.
Participants USA
54 children in
primary care or emergency department aged 5 to 19 years with ear pain and eardrum findings indicative of
AOM.
Interventions Treatment: anaesthetic ear drops (antipyrine, benzocaine, glycerine)
Control: olive oil drops
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Characteristics of included studies (Continued )
Duration: 30 minutes
All children were also given acetaminophen (15 mg/kg in a single dose)
Outcomes Ear pain was assessed by means of 2 visual analog scales at baseline, 10, 20, 30 minutes after instillation, and
an average ear pain score was determined.
Four measures were used:
1) proportion of subjects who showed 50% reduction
2) proportion of subjects who showed 25% reduction
3) proportion of subjects who showed a 1 or more point reduction
4) mean score over time
Notes
Allocation concealment B – Unclear
Study Sarrell 2001
Methods R= randomisation claimed, but method not described.
Baseline comparability stated.
Double blind
Not intention to treat (7 of 110 patients excluded).
Participants Israel
103 children aged 6 to 18 years who were diagnosed with otalgia associated with AOM.
Interventions Treatment: anaesthetic ear drops (ametocaine, phenazone, glycerine) Control: naturopathic ear drops (Allium
sativum, Verbascum thapsus, Calendula flores, Hypericum perforatum in olive oil).
Drops were instilled three times daily for three days.
All children were also given acetaminophen (15 mg/kg in a single dose).
Duration: Three days
Outcomes Ear pain was assessed using 2 visual analog scales, and an overall ear pain score was determined. The first
data point was assessed at the diagnosis of AOM and then pain was assessed during three days; before the
drops were instilled, and at 15 and 30 minutes after instillation. Outcome: mean pain score
Notes
Allocation concealment B – Unclear
Study Sarrell 2003a
Methods R= computer-numbered randomisation. Baseline comparability documented.
Identical bottles.
Double blind.
Not intention to treat (4 of 90 patients were excluded).
Participants Israel
86 children in an ambulatory clinic aged 5 to 18 years with ear pain caused by AOM.
Interventions Treatment: anaesthetic ear drops (ametocaine, phenazone, glycerine) Control: naturopathic ear drops (Allium
sativum, Verbascum thapsus, Calendula flores, Hypericum perforatum, lavendulla officinalis and Vitamin E
in olive oil).
Drops were instilled three times daily for three days.
Duration: Three days
Outcomes Ear pain was assessed using 2 visual analog scales, and an overall ear pain score was determined. The first
data point was assessed at the diagnosis of AOM and then pain was assessed during three days; before the
drops were installed, and at 15 and 30 minutes after instillation. Outcome: mean pain score
Notes
Allocation concealment B – Unclear
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Study Sarrell 2003b
Methods R= computer-numbered randomisation.
Baseline comparability documented.
Ear drops in identical bottles.
Double blind.
Not intention to treat (5 of 90 patients were excluded).
Participants Israel
85 children in an ambulatory clinic aged 5 to 18 years with ear pain caused by AOM.
Interventions Treatment: anaesthetic ear drops (ametocaine, phenazone, glycerine) Control: naturopathic ear drops (Allium
sativum, Verbascum thapsus, Calendula flores, Hypericum perforatum, lavendulla officinalis and Vitamin E
in olive oil).
Drops were instilled three times daily for three days.
All children were also given oral amoxicillin (80mg/kg/day divided into three doses).
Duration: Three days
Outcomes Ear pain was assessed using 2 visual analog scales, and an overall ear pain score was determined. The first
data point was assessed at the diagnosis of AOM and then pain was assessed during three days; before the
drops were installed, and at 15 and 30 minutes after instillation. Outcome: mean pain score
Notes
Allocation concealment B – Unclear
Characteristics of excluded studies
Study Reason for exclusion
Abramson 1969 For surgery, not for AOM
Brunet 1970 No control group
Busmann 1967 No original data, review only
Comeau 1978 Iontophoresis.
For myringotomy or ventilation tube placement, not AOM
Fay 2003 No original data, comments on a previous trial (Sarrell 2003a; Sarrell 2003b).
Fort 2000 Oral not topical administration of pain relief
Francois 1993 Treatment of congestive myringitis, not AOM
Francois 1995 No original data, an overview
Koeppel 1970 No original data, review only
Lacher 1969 No control group
Laszlo 1981 Anaesthesia of tympanic membrane, not for AOM
Laxdal 1970 Not double-blinded; intervention not appropriate
MacPhail 1996 Descriptive article
Matz 2001a Not double-blinded; intervention not appropriate
Matz 2001b No original data, referring to data in an unpublished study (Matz)
McConaghy 2001 No original data; review only
Menshikov 1968 No control group
Millard 1969 No control group
Polyakova 1991 Unclear if randomised and blinded, unable to contact authors
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Characteristics of excluded studies (Continued )
Reiss 2002 No original data; an overview
Sano 1995 No original data; an overview
Shikowitz 1989 No original data; review only
Silverstein 1969 No control group; for insertion of tympanic membrane tubes, not for AOM
Weippl 1985 Neither randomised nor double-blinded; oral treatment
Willenberg 1975 No control group
Woldman 1998 No original data; comments on a previous trial (Hoberman 1997)
A N A L Y S E S
Comparison 01. Anaesthetic versus placebo
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 25% reduction in ear pain Relative Risk (Fixed) 95% CI Totals not selected
07 50% reduction in ear pain Relative Risk (Fixed) 95% CI Totals not selected
Comparison 02. Anaeshethic versus naturopathic
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Mean pain score, day 1 Weighted Mean Difference (Random) 95% CI Subtotals only
02 Mean pain score, day 2 Weighted Mean Difference (Random) 95% CI Subtotals only
03 Mean pain score, day 3 Weighted Mean Difference (Random) 95% CI Subtotals only
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Analysis 01.01. Comparison 01 Anaesthetic versus placebo, Outcome 01 25% reduction in ear pain
Review: Topical analgesia for acute otitis media
Comparison: 01 Anaesthetic versus placebo
Outcome: 01 25% reduction in ear pain
Study Anaesthetic drops Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 10 minutes after instillation
Hoberman 1997 13/27 11/27 1.18 [ 0.65, 2.15 ]
02 20 minutes after instillation
Hoberman 1997 21/27 17/27 1.24 [ 0.87, 1.76 ]
03 30 minutes after instillation
Hoberman 1997 26/27 19/27 1.37 [ 1.06, 1.77 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours anaesthetic
Analysis 01.07. Comparison 01 Anaesthetic versus placebo, Outcome 07 50% reduction in ear pain
Review: Topical analgesia for acute otitis media
Comparison: 01 Anaesthetic versus placebo
Outcome: 07 50% reduction in ear pain
Study Anaesthetic drops Placebo Relative Risk (Fixed) Relative Risk (Fixed)
n/N n/N 95% CI 95% CI
01 10 minutes after instillation
Hoberman 1997 9/27 4/27 2.25 [ 0.79, 6.43 ]
02 20 minutes after instillation
Hoberman 1997 13/27 12/27 1.08 [ 0.61, 1.93 ]
03 30 minutes after instillation
Hoberman 1997 21/27 15/27 1.40 [ 0.95, 2.07 ]
0.1 0.2 0.5 1 2 5 10
Favours placebo Favours anaesthetic
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Analysis 02.01. Comparison 02 Anaeshethic versus naturopathic, Outcome 01 Mean pain score, day 1
Review: Topical analgesia for acute otitis media
Comparison: 02 Anaeshethic versus naturopathic
Outcome: 01 Mean pain score, day 1
Study Anaesthetic drops Naturopathic drops Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Baseline
Sarrell 2001 42 8.53 (1.90) 61 8.46 (1.50) 31.9 0.07 [ -0.62, 0.76 ]
Sarrell 2003a 42 7.80 (1.90) 44 8.40 (1.50) 30.3 -0.60 [ -1.33, 0.13 ]
Sarrell 2003b 43 9.10 (1.10) 42 8.70 (1.50) 37.8 0.40 [ -0.16, 0.96 ]
Subtotal (95% CI) 127 147 100.0 -0.01 [ -0.58, 0.56 ]
Test for heterogeneity chi-square=4.58 df=2 p=0.10 I² =56.3%
Test for overall effect z=0.03 p=1
02 15 minutes after instillation
Sarrell 2001 42 5.60 (2.50) 61 4.80 (2.30) 33.6 0.80 [ -0.15, 1.75 ]
Sarrell 2003a 42 4.30 (2.30) 44 4.70 (2.30) 33.2 -0.40 [ -1.37, 0.57 ]
Sarrell 2003b 43 6.70 (1.90) 42 5.20 (2.60) 33.2 1.50 [ 0.53, 2.47 ]
Subtotal (95% CI) 127 147 100.0 0.63 [ -0.45, 1.71 ]
Test for heterogeneity chi-square=7.52 df=2 p=0.02 I² =73.4%
Test for overall effect z=1.15 p=0.2
03 30 minutes after instillation
Sarrell 2001 42 4.30 (2.30) 61 3.10 (2.00) 33.9 1.20 [ 0.34, 2.06 ]
Sarrell 2003a 42 2.90 (1.60) 44 3.00 (2.00) 35.1 -0.10 [ -0.86, 0.66 ]
Sarrell 2003b 43 5.60 (2.60) 42 3.50 (2.50) 31.0 2.10 [ 1.02, 3.18 ]
Subtotal (95% CI) 127 147 100.0 1.02 [ -0.22, 2.27 ]
Test for heterogeneity chi-square=11.68 df=2 p=0.003 I² =82.9%
Test for overall effect z=1.61 p=0.1
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Analysis 02.02. Comparison 02 Anaeshethic versus naturopathic, Outcome 02 Mean pain score, day 2
Review: Topical analgesia for acute otitis media
Comparison: 02 Anaeshethic versus naturopathic
Outcome: 02 Mean pain score, day 2
Study Anaesthetic drops Naturopathic drops Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Before instillation
Sarrell 2001 42 3.10 (1.60) 61 2.60 (1.70) 49.4 0.50 [ -0.15, 1.15 ]
Sarrell 2003a 42 2.30 (1.30) 44 1.80 (1.70) 50.6 0.50 [ -0.14, 1.14 ]
Subtotal (95% CI) 84 105 100.0 0.50 [ 0.05, 0.95 ]
Test for heterogeneity chi-square=0.00 df=1 p=1.00 I² =0.0%
Test for overall effect z=2.16 p=0.03
02 15 minutes after instillation
Sarrell 2001 42 2.60 (1.30) 61 1.80 (1.20) 49.8 0.80 [ 0.30, 1.30 ]
Sarrell 2003a 42 1.80 (1.10) 44 1.70 (1.20) 50.2 0.10 [ -0.39, 0.59 ]
Subtotal (95% CI) 84 105 100.0 0.45 [ -0.24, 1.13 ]
Test for heterogeneity chi-square=3.91 df=1 p=0.05 I² =74.4%
Test for overall effect z=1.28 p=0.2
03 30 minutes after instillation
Sarrell 2001 42 2.10 (1.10) 61 1.40 (0.90) 48.8 0.70 [ 0.30, 1.10 ]
Sarrell 2003a 42 1.40 (0.80) 44 1.30 (0.90) 51.2 0.10 [ -0.26, 0.46 ]
Subtotal (95% CI) 84 105 100.0 0.39 [ -0.19, 0.98 ]
Test for heterogeneity chi-square=4.75 df=1 p=0.03 I² =79.0%
Test for overall effect z=1.31 p=0.2
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Analysis 02.03. Comparison 02 Anaeshethic versus naturopathic, Outcome 03 Mean pain score, day 3
Review: Topical analgesia for acute otitis media
Comparison: 02 Anaeshethic versus naturopathic
Outcome: 03 Mean pain score, day 3
Study Anaesthetic drops Naturopathic drops Weighted Mean Difference (Random) Weight Weighted Mean Difference (Random)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
01 Before instillation
Sarrell 2001 42 1.60 (0.80) 61 1.20 (0.60) 44.5 0.40 [ 0.12, 0.68 ]
Sarrell 2003a 42 1.40 (0.60) 44 1.20 (0.60) 55.5 0.20 [ -0.05, 0.45 ]
Subtotal (95% CI) 84 105 100.0 0.29 [ 0.09, 0.48 ]
Test for heterogeneity chi-square=1.06 df=1 p=0.30 I² =5.3%
Test for overall effect z=2.91 p=0.004
02 15 minutes after instillation
Sarrell 2001 42 1.60 (0.80) 61 1.20 (0.60) 44.7 0.40 [ 0.12, 0.68 ]
Sarrell 2003a 42 1.20 (0.50) 44 1.10 (0.50) 55.3 0.10 [ -0.11, 0.31 ]
Subtotal (95% CI) 84 105 100.0 0.23 [ -0.06, 0.53 ]
Test for heterogeneity chi-square=2.75 df=1 p=0.10 I² =63.6%
Test for overall effect z=1.57 p=0.1
03 30 minutes after instillation
Sarrell 2001 42 1.40 (0.60) 61 1.10 (0.48) 50.2 0.30 [ 0.08, 0.52 ]
Sarrell 2003a 42 1.20 (0.50) 44 0.30 (0.60) 49.8 0.90 [ 0.67, 1.13 ]
Subtotal (95% CI) 84 105 100.0 0.60 [ 0.01, 1.19 ]
Test for heterogeneity chi-square=13.59 df=1 p=0.0002 I² =92.6%
Test for overall effect z=2.00 p=0.05
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